Several next-generation ADC programmes, including PSMA- and B7-H3-directed agents such as MEDI3726 and DS-7300, have reported early antitumour activity signals. At the same time, the global development landscape remains fragmented across targets, payload classes, endpoints, and sponsor types. This study therefore aimed to map the contemporary landscape of ADC clinical trials for prostatic neoplasms, clarify current development patterns, identify translational opportunities and gaps, and provide an integrated overview to support future clinical development.

9 days ago

Journal

CD276 (CD276 Molecule)

ifinatamab deruxtecan (DS-7300) • MEDI3726

11d

QLC5508 in Participants With Metastatic Prostate Cancer (clinicaltrials.gov)

P3, N=700, Not yet recruiting, Qilu Pharmaceutical Co., Ltd.

11 days ago

New P3 trial

docetaxel • MHB088C

11d

BGB-C354-101: A First-in-Human Study of BGB-C354 Alone and in Combination With Tislelizumab in Participants With Advanced Solid Tumors (clinicaltrials.gov)

P1, N=63, Completed, BeOne Medicines | Active, not recruiting --> Completed | N=120 --> 63 | Trial completion date: Jan 2027 --> May 2026 | Trial primary completion date: Dec 2026 --> May 2026

11 days ago

Trial completion • Enrollment change • Trial completion date • Trial primary completion date • First-in-human

Tevimbra (tislelizumab-jsgr)

14d

A Study of Ifinatamab Deruxtecan in Pediatric Participants With Relapsed or Refractory Solid Tumors (MK-9999-01D/LIGHTBEAM-U01) (clinicaltrials.gov)

P1/2, N=134, Not yet recruiting, Merck Sharp & Dohme LLC

14 days ago

New P1/2 trial

ifinatamab deruxtecan (DS-7300)

16d

A Study of HS-20093 in Patients With Pretreated Advanced or Metastatic Esophageal Squamous Cell Carcinoma (ESCC) (clinicaltrials.gov)

P3, N=494, Not yet recruiting, Hansoh BioMedical R&D Company

16 days ago

New P3 trial

paclitaxel • docetaxel • irinotecan • risvutatug rezetecan (GSK5764227)

17d

QLC5508 in Advanced Solid Tumors:: C-QTc, Pharmacokinetics (PK) Comparisons and Drug-drug Interaction (clinicaltrials.gov)

P1, N=48, Not yet recruiting, Qilu Pharmaceutical Co., Ltd.

17 days ago

New P1 trial

Nubeqa (darolutamide) • itraconazole • MHB088C • rifampicin

17d

A Clinical Study of QLC5508 and/or QLH12016 in Combination With Other Anti-tumor Therapies in Subjects With Advanced Prostate Cancer (clinicaltrials.gov)

P1/2, N=212, Recruiting, Qilu Pharmaceutical Co., Ltd. | Not yet recruiting --> Recruiting

17 days ago

Enrollment open

enzalutamide • abiraterone acetate • MHB088C

19d

Molecular Design and Preclinical Evaluation of GenSci143, a Novel B7-H3- and PSMA-Directed Bispecific Antibody-Drug Conjugate, for the Treatment of Prostate Cancer. (PubMed, Mol Cancer Ther)

The compelling preclinical efficacy across cancer models with varying levels of target antigen expression and its exceptional plasma stability support the translational relevance of GenSci143. These results indicate that GenSci143 is a promising therapeutic candidate for castration resistant PCa and potentially other malignancies, warranting its further clinical development.

19 days ago

Preclinical • Journal

CD276 (CD276 Molecule)

22d

A Phase 1 Study of NEOK001, a B7-H3 and ROR1 Targeting Bispecific ADC in Participants With Select Solid Tumors (clinicaltrials.gov)

P1, N=155, Recruiting, NEOK Bio, Inc.

22 days ago

New P1 trial • First-in-human

23d

A clinical trial of ifinatamab deruxtecan in people under age 18 who have certain types of cancer (MK-9999-01D) (2025-522339-32-00)

P1/2, N=4, Not yet recruiting, Merck Sharp & Dohme LLC

23 days ago